Qubigen to Attend Discovery on Target 2025 in Boston
- David Brooks
- Sep 16
- 1 min read
Qubigen is pleased to announce that Matthew Oristano, Strategic Advisor and Investor in Qubigen, will be attending Discovery on Target (DOT) 2025 in Boston, taking place on September 22nd–25th, 2025.
Discovery on Target is a leading international conference bringing together experts from biotechnology, pharmaceuticals, and academia to discuss the latest advances in drug discovery. The event is widely recognized for its focus on emerging technologies for identifying and validating novel targets, and for developing innovative therapeutics, addressing some of the toughest challenges in modern medicine.
Matthew Oristano will represent Qubigen in Boston, with a focus on exploring strategic relationships, collaborations, and investor opportunities. His attendance underscores Qubigen’s commitment to expanding partnerships and applying our Federated AI-driven drug design platform to a broader range of therapeutic targets.
Qubigen’s platform combines privacy-preserving Federated AI, a growing virtual network of federated datasets, and advanced quantum chemistry-based virtual screening to generate novel, small molecule drugs optimized for drug-like properties and synthesizability. By securely leveraging global data, we deliver accelerated drug design programs while ensuring that sensitive data and IP remain fully protected.
We look forward to engaging with potential partners and stakeholders at Discovery on Target 2025 and to advancing opportunities for collaboration that can drive meaningful progress in drug design and development.
To get in touch with Matt: |
|---|
Qubigen - accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
